GSK’s anti-BCMA Therapy Notches FDA Approval for Refractory Multiple Myeloma
On August 6th, the company announced that the USFDA has granted accelerated approval to BLENREP as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma, making it …
Read More